We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
Intrommune Therapeutics is a New York City-based biopharmaceutical company develop...
Intrommune Therapeutics is a New York City-base...
Molecular Templates is focused on the discovery, development, and commercializatio...
Molecular Templates is focused on the discovery...
MediWound is a fully integrated biopharmaceutical company focused on developing, m...
MediWound is a fully integrated biopharmaceutic...
DelMar Pharmaceuticals is a biopharmaceutical company focused on the development a...
DelMar Pharmaceuticals is a biopharmaceutical c...
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Join the National Investor Network and get the latest information with your interests in mind.